Lupin Limited — Updates, 07-03-2025: Press Release

Lupin has launched Rivaroxaban Tablets USP, 2.5 mg, in the U.S. following final FDA approval of its Abbreviated New Drug Application. This product is bioequivalent to Xarelto® Tablets and is indicated to reduce the risk of major cardiovascular events in patients with coronary artery disease and to lower the risk of major thrombotic vascular events in patients with peripheral artery disease, particularly after recent lower extremity revascularization. The estimated annual sales for Rivaroxaban Tablets in the U.S. were USD 446 million as of January 2025. This launch enhances Lupin's position in the cardiovascular therapeutic area and presents a potential growth opportunity by tapping into the sizeable market for similar products.